https://orcid.org/0000-0002-4272-4993
References
- Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N Engl J Med. 2020;382(13):1268–1269. doi:https://doi.org/10.1056/NEJMe2002387.
- Cao Y, Liu X, Xiong L. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020. doi:https://doi.org/10.1002/jmv.25822.
- Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8(5):436–438. doi:https://doi.org/10.1016/S2213-2600(20)30167-3.
- Oliver N, Barber XG, Roomp K, Roomp, K. The Covid19Impact survey: assessing the pulse of the COVID-19 pandemic in Spain via 24 questions. arXiv preprint. arXiv:2004.01014, 2020.
- Hess DR. What is evidence-based medicine and why should I care? Respir Care. 2004;49(7):730–741.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2020. Available from: www.ginaasthma.org [last accessed 1 April 2020].
- National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Severe Asthma (NICE guideline [NG166]) 2020. Available from: https://www.nice.org.uk/guidance/ng166 [last accessed 10 April 2020].
- British Thoracic Society. Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 2020. Available from: https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-advice-for-healthcare-professionals-treating-patients-with-asthma/ [last accessed 10 April 2020].
- National Asthma Council Australia. Australian Asthma Handbook - Managing Asthma during the COVID-19 (SARS-CoV-2) Pandemic 2020. Available from: https://www.asthmahandbook.org.au/clinical-issues/covid-19 [last accessed 10 April 2020].
- Harber P, Santiago S, Bansal S, Liu Y, Yun D, Wu S. Respirator physiologic impact in persons with mild respiratory disease. J Occup Environ Med. 2010;52(2):155–162. doi:https://doi.org/10.1097/JOM.0b013e3181ca0ec9.
- Cadogan CA, Hughes CM. On the frontline against COVID-19: community pharmacists' contribution during a public health crisis. Res Social Adm Pharm. 2020;S1551-7411(20)30292-8. doi:https://doi.org/10.1016/j.sapharm.2020.03.015.
- Peterson OK, Thankom A. Spillover of COVID-19: Impact on the Global Economy 27 March 2020. Available from: https://ssrn.com/abstract=3562570 [last accessed 11 April 2020].
- World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim Guidance, 13 March 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf [last accessed 30 April 2020].
- Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi:https://doi.org/10.1371/journal.pmed.0030343.
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London, England). 2020;395(10223):473–475. doi:https://doi.org/10.1016/S0140-6736(20)30317-2.
- American College of Allergy, Asthma and Immunology. 2020. Nebulizer use during the COVID-19 Pandemic. Available from: https://college.acaai.org/publications/college-insider/nebulizer-use-during-covid-19-pandemic [last accessed 10 April 2020].
- Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020;167:105987. doi:https://doi.org/10.1016/j.rmed.2020.105987.
- Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ. 2020;192(13):E346doi:https://doi.org/10.1503/cmaj.75066.
- Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;2013(9):CD000052. doi:https://doi.org/10.1002/14651858.CD000052.pub3.
- Center for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) - Symptoms of Coronavirus 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [last accessed 11 April 2020].
- Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, Guo Z, Wu H-X, Bai Y. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.17.20037572.
- Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411–415. doi:https://doi.org/10.15585/mmwr.mm6914e1.
- National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NICE guideline [NG165]) 2020. Available from: https://www.nice.org.uk/guidance/ng165 [last accessed 10 April 2020].
- Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004;113(3):415–419. doi:https://doi.org/10.1016/j.jaci.2003.11.034.
- Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, Ansotegui IJ, Bedbrook A, Bosnic-Anticevich S, Canonica GW, et al; ARIA-MASK study group. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020. doi:https://doi.org/10.1111/all.14302.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306. doi:https://doi.org/10.1038/d41573-020-00073-5.
- Mendelson M. Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS-CoV-2 to fragile health systems of southern hemisphere countries this winter? Int J Infect Dis. 2020;94:32–33. doi:https://doi.org/10.1016/j.ijid.2020.03.030.